Vmbook Online ordering

Eleven Biotherapeutics Inc

Eleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of targeted protein therapeutics for the treatment of patients with severe eye diseases. The company's lead product candidate, Vicinium, is a recombinant fusion protein that combines a monoclonal antibody fragment targeting epithelial cell adhesion molecule (EpCAM) with a truncated form of Pseudomonas exotoxin A for the treatment of cancer.

Eleven Biotherapeutics is listed on the NASDAQ stock exchange under the ticker symbol "EBIO". The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.

As of the time of writing, the company's market capitalization is around $15 million, making it a small-cap company. The company's stock has been highly volatile in the past and has not performed well in the last few years.

Eleven Biotherapeutics has a pipelined of product candidates for the treatment of various eye diseases like